West Pharma Lifts Outlook On Surging GLP-1 Demand, Stock Soars
1. WST reported exceptional earnings, beating expectations and raising guidance. 2. Adjusted EPS rose to $1.84, surpassing consensus of $1.51. 3. Sales increased to $766.5 million, outperforming the $726.45 million consensus. 4. High-Value Products segment drove growth, particularly in GLP-1 elastomer products. 5. Company raised full-year EPS guidance to $6.65-$6.85 from $6.15-$6.35.